Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01392326




Registration number
NCT01392326
Ethics application status
Date submitted
7/07/2011
Date registered
12/07/2011
Date last updated
4/02/2016

Titles & IDs
Public title
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Scientific title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis
Secondary ID [1] 0 0
2011-000276-34
Secondary ID [2] 0 0
CAIN457F2306
Universal Trial Number (UTN)
Trial acronym
FUTURE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Secukinumab (75 mg)
Treatment: Drugs - Secukinumab (150 mg)
Treatment: Drugs - Placebo Comparator

Experimental: Group 1 - Secukinumab (75mg)

Experimental: Group 2 - Secukinumab (150 mg)

Placebo comparator: Group 3 -


Treatment: Drugs: Secukinumab (75 mg)
Secukinumab (75 mg)

Treatment: Drugs: Secukinumab (150 mg)
Secukinumab (150 mg)

Treatment: Drugs: Placebo Comparator
Placebo Comparator
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Percent of Subjects Achieving a PASI75 Response in the Subgroup of Subjects Who Have =3% Skin Involvement With Psoriasis at Baseline
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percent of Subjects Achieving a PASI90 Response in the Subgroup of Subjects Who Have =3% Skin Involvement With Psoriasis at Baseline
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Change From Baseline in DAS28-CRP for Secukinumab 75 or 150 mg
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
Change From Baseline in SF36-PCS for Secukinumab 75 or 150 mg
Timepoint [4] 0 0
Week 24
Secondary outcome [5] 0 0
Change From Baseline in HAQ-DI for Secukinumab 75 or 150 mg
Timepoint [5] 0 0
Week 24
Secondary outcome [6] 0 0
Percent of Patients Achieving ACR50 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo
Timepoint [6] 0 0
Week 24
Secondary outcome [7] 0 0
Change From Baseline for Joint/Bone Structural Damage (Van Der Heijde Modified Total Sharp Score) for Secukinumab 75 and 150 mg (Pooled Doses)
Timepoint [7] 0 0
Week 24
Secondary outcome [8] 0 0
Percent of Patients With Dactylitis in the Subset of Subjects Who Have Dactylitis at Baseline
Timepoint [8] 0 0
Week 24
Secondary outcome [9] 0 0
Percent of Patients With Enthesitis in the Subset of Subjects Who Have Enthesitis at Baseline
Timepoint [9] 0 0
Week 24

Eligibility
Key inclusion criteria
Inclusion criteria:

* Male or non-pregnant, non-lactating female patients at least 18 years of age
* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline =3 tender joints out of 78 and =3 swollen out of 76 (dactylitis of a digit counts as one joint each)
* Rheumatoid factor and anti-CCP antibodies negative
* Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of =2cm diameter or nail changes consistent with psoriasis or documented history o plaque psoriasis
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Chest X-ray with evidence of ongoing infectious or malignant process
* Subjects who have previously been treated with more than 3 different TNFa inhibitors
* Subjects taking high potency opioid analgesics
* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFa Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2014
Sample size
Target
Accrual to date
Final
606
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Maroochydore
Recruitment hospital [2] 0 0
Novartis Investigative Site - Malvern
Recruitment postcode(s) [1] 0 0
4558 - Maroochydore
Recruitment postcode(s) [2] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Nebraska
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Santa Fe
Country [21] 0 0
Argentina
State/province [21] 0 0
Cordoba
Country [22] 0 0
Belgium
State/province [22] 0 0
Genk
Country [23] 0 0
Belgium
State/province [23] 0 0
Gent
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Brazil
State/province [25] 0 0
RS
Country [26] 0 0
Brazil
State/province [26] 0 0
SP
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Pleven
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Sevlievo
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Sofia
Country [30] 0 0
Canada
State/province [30] 0 0
Newfoundland and Labrador
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Czech Republic
State/province [33] 0 0
Bruntal
Country [34] 0 0
Czech Republic
State/province [34] 0 0
Uherske Hradiste
Country [35] 0 0
Czech Republic
State/province [35] 0 0
Zlin
Country [36] 0 0
Germany
State/province [36] 0 0
Aachen
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Erlangen
Country [39] 0 0
Germany
State/province [39] 0 0
Gommern
Country [40] 0 0
Germany
State/province [40] 0 0
Hamburg
Country [41] 0 0
Germany
State/province [41] 0 0
Herne
Country [42] 0 0
Germany
State/province [42] 0 0
Hildesheim
Country [43] 0 0
Germany
State/province [43] 0 0
Koeln
Country [44] 0 0
Germany
State/province [44] 0 0
Leipzig
Country [45] 0 0
Germany
State/province [45] 0 0
Nürnberg
Country [46] 0 0
Germany
State/province [46] 0 0
Ratingen
Country [47] 0 0
Germany
State/province [47] 0 0
Zerbst
Country [48] 0 0
Israel
State/province [48] 0 0
Ashkelon
Country [49] 0 0
Israel
State/province [49] 0 0
Haifa
Country [50] 0 0
Israel
State/province [50] 0 0
Ramat Gan
Country [51] 0 0
Israel
State/province [51] 0 0
Tel-Aviv
Country [52] 0 0
Italy
State/province [52] 0 0
(vr)
Country [53] 0 0
Italy
State/province [53] 0 0
CT
Country [54] 0 0
Italy
State/province [54] 0 0
PO
Country [55] 0 0
Italy
State/province [55] 0 0
SI
Country [56] 0 0
Philippines
State/province [56] 0 0
Batangas
Country [57] 0 0
Philippines
State/province [57] 0 0
Cavite
Country [58] 0 0
Philippines
State/province [58] 0 0
Metro Manila
Country [59] 0 0
Philippines
State/province [59] 0 0
Las Pinas
Country [60] 0 0
Philippines
State/province [60] 0 0
Manila
Country [61] 0 0
Philippines
State/province [61] 0 0
Quezon City
Country [62] 0 0
Poland
State/province [62] 0 0
Bialystok
Country [63] 0 0
Poland
State/province [63] 0 0
Warszawa
Country [64] 0 0
Romania
State/province [64] 0 0
District 1
Country [65] 0 0
Romania
State/province [65] 0 0
Bucharest
Country [66] 0 0
Romania
State/province [66] 0 0
Cluj Napoca
Country [67] 0 0
Romania
State/province [67] 0 0
Iasi
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Ekaterinburg
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Kemerovo
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Moscow
Country [71] 0 0
Russian Federation
State/province [71] 0 0
St-Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Yaroslavl
Country [73] 0 0
Singapore
State/province [73] 0 0
Singapore
Country [74] 0 0
Slovakia
State/province [74] 0 0
Slovak Republic
Country [75] 0 0
Slovakia
State/province [75] 0 0
Lucenec
Country [76] 0 0
Thailand
State/province [76] 0 0
Bangkok
Country [77] 0 0
Thailand
State/province [77] 0 0
Chiang Mai
Country [78] 0 0
Thailand
State/province [78] 0 0
Khon Kaen
Country [79] 0 0
United Kingdom
State/province [79] 0 0
England
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Staffordshire
Country [81] 0 0
United Kingdom
State/province [81] 0 0
West Yorkshire
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Glasgow
Country [83] 0 0
United Kingdom
State/province [83] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFa inhibitor therapy.
Trial website
https://clinicaltrials.gov/study/NCT01392326
Trial related presentations / publications
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14.
Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. J Rheumatol. 2020 Apr;47(4):539-547. doi: 10.3899/jrheum.190116. Epub 2019 Jun 15.
Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355. doi: 10.1002/acr.23111.
Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203-207. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01392326